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Abstract
Background: Aboriginal Australians have higher cancer mortality than non-Aboriginal
Australians. Lower rates of cancer treatment among Aboriginal people can contribute
to this.
Aims: To investigate demographic, clinical and access factors associated with lung,
breast and bowel cancer treatment for Aboriginal people compared with non-Aborigi-
nal people in New South Wales, Australia.
Methods: Population-based cohort study using linked routinely collected datasets,
including all diagnoses of primary lung, breast or bowel cancer from January 2009 to
June 2012. Treatment (surgery, radiotherapy or chemotherapy) within 6 months from
diagnosis was measured. Access was measured using minimum distance to radiother-
apy or hospital with a cancer-specific multidisciplinary team, visit to a specialist and
possession of private health insurance. Logistic regression modelling was employed.
Results: There were 587 Aboriginal and 34 015 non-Aboriginal people diagnosed with
cancer. For lung cancer, significantly fewer Aboriginal than non-Aboriginal people
received surgery (odds ratio 0.46, 95% confidence interval 0.29–0.73, P < 0.001) or
any treatment (surgery, chemotherapy or radiotherapy; odds ratio 0.64, 95% confi-
dence interval 0.47–0.88, P = 0.006) after adjusting for sex, age, disease extent and
comorbidities. They were less likely to have an attendance with a surgeon (27.0%, 62/
230 vs 33.3%, 2865/8597, P = 0.04) compared with non-Aboriginal people. There were
no significant differences in cancer treatment for Aboriginal people compared with
non-Aboriginal people for breast or bowel cancers after adjusting for patient sex, age,
disease extent and comorbidities.
Conclusion: Aboriginal people were significantly less likely to receive surgery for lung
cancer than non-Aboriginal people and had fewer attendances with a surgeon,
suggesting a need to strengthen referral pathways.
Introduction
Aboriginal Australians have shorter life expectancy than
non-Aboriginal Australians.1 This is driven by higher mor-
tality rates from diseases including circulatory disease1 (1.6
times the non-indigenous rate), diabetes1 (six times the
non-indigenous rate), kidney disease1 (2.6 times the non-
indigenous rate) and cancer2 (1.4 times the non-indige-
nous rate). Cancer mortality rates decreased by 13% for
non-Aboriginal people over 1998 to 2015, but worryingly
increased by 21% for Aboriginal people.1
The reasons for this disparity in cancer mortality rates
are complex and include patient factors and healthcare
factors.3 The disparity is partly explained by Aboriginal
people having a higher prevalence of risk factors1 (e.g.
smoking, alcohol use, obesity) that increase cancer inci-
dence, including cancers with poorer prognosis,4 and
increase the prevalence of comorbid conditions that can
negatively impact on cancer survival.5 More advanced
disease at diagnosis5,6 contributes to higher mortality.
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ICD-10-AM, International Statistical Classification of Diseases and
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Variations in treatment also contribute to the differences
in mortality. Aboriginal people reportedly have lower use
of cancer treatments,5–11 and higher likelihood of sub-opti-
mal treatment compared with guidelines than non-Aborigi-
nal people.12 In New South Wales (NSW), Aboriginal
people were less likely to receive surgery than non-Aborigi-
nal people for non-metastatic non-small cell lung cancer,13
breast cancer8 and localised or regional prostate cancer.9
Similar surgery rates were observed between Aboriginal
and non-Aboriginal people for colorectal cancer.14 Cancer
treatment can be complex, requiring consultation with spe-
cialists and treatment in specialist centres. It can require
travel and time away from home, and can incur substantial
out-of-pocket costs. Providing person-centred care that is
integrated across health sectors and provides optimal and
culturally appropriate care is a priority in improving out-
comes for Aboriginal and Torres Strait Islander people.15
To date, no NSW population-level studies have com-
pared chemotherapy or radiotherapy cancer treatment
for Aboriginal people and non-Aboriginal people. This
study brings together population-level surgery, radio-
therapy and chemotherapy data for the first time in
NSW. Three of the most frequently diagnosed cancers
among Aboriginal people are analysed: breast, lung and
bowel cancers. We aim to confirm the surgical treatment
patterns identified in other NSW studies, and to explore
any differences in radiotherapy and chemotherapy treat-
ment patterns. A further goal is to explore whether
travel distance, use of specialists or private health insur-
ance status impact on people receiving treatment.
Methods
Study design
The study was designed in consultation with the Cancer
Institute NSW’s Aboriginal Advisory Group which provides
Aboriginal community representation by Aboriginal
people.
A population-based, retrospective cohort study was con-
ducted using linked routinely collected data from the NSW
Cancer Registry16 (NSWCR), NSW Admitted Patient Data
Collection (APDC), Medicare Benefits Schedule (MBS),
Pharmaceutical Benefits Scheme (PBS) and NSW Outpa-
tient Radiation Oncology Dataset (RD).
The NSWCR is a statutory population-based register of
all invasive cancer cases (excluding non-melanoma skin
cancer) diagnosed in NSW residents since 1972. The NSW
APDC, maintained by the NSW Ministry of Health with
mandatory reporting, contains all admissions to NSW pub-
lic and private hospitals. The RD contains demographic
and clinical details for outpatient radiation oncology treat-
ments at public and private facilities in NSW. Probabilistic
data linkage was performed by the Centre for Health
Record Linkage with an estimated false-positive linkage
rate of five per 1000.17
The MBS contains information on Medicare services
including outpatient and some in-hospital procedures,
the PBS includes information about Commonwealth gov-
ernment-subsidised dispensed prescription medicines.18
These were linked to the NSWCR cancer cohort by the
Australian Institute of Health and Welfare (AIHW).
Approval for this study was from the NSW Population
and Health Services Research Ethics Committee (HREC/
15/CIPHS/15), AIHW Ethics Committee (EO2016/1/224)
and Aboriginal Health and Medical Research Council
Ethics Committee (1201/16).
Study population
Adults aged over 17 diagnosed with a first primary lung,
bowel or breast (women only) cancer between January
2009 and June 2012 were identified from the NSWCR.
The International Statistical Classification of Diseases and
Related Health Problems, 10th Revision, Australian Modi-
fication (ICD-1O-AM) identified cancer type using codes
C34 (lung), C50 (breast), C18-C20 (bowel). Residents of
local health districts next to the NSW border were
excluded (Northern NSW, Southern NSW, Murrum-
bidgee, Far West and Albury) because these residents
often visit interstate hospitals and therefore treatment
capture is incomplete in the study datasets. Aboriginal
and Torres Strait Islander status was assigned using
Aboriginality information in the NSWCR, APDC, NSW
Emergency Department Data Collection and the Cause of
Death Unit Record File (held by the NSW Ministry of
Health Secure Analytics for Population Health Research
and Intelligence) using a ‘weight of evidence’method.19
Outcome variables
Treatments within 6 months from diagnosis were identi-
fied from the linked data. Procedure codes, diagnosis
codes, MBS item numbers and PBS Anatomical Thera-
peutic Chemical codes used in defining treatment are
listed in Supporting Information Table S1. Surgical pro-
cedure codes were defined by a Clinical Advisory Group.
Public and private inpatient and outpatient radiotherapy
were identified from the APDC, RD and MBS data. Pub-
lic and private inpatient and outpatient chemotherapy
were identified from the APDC, MBS and PBS data.20
Adjustment variables
Several factors may influence treatment decisions.
Demographic factors were age at diagnosis, sex (except
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breast cancer), remoteness of residence (using the Acces-
sibility/Remoteness Index of Australia21), and socioeco-
nomic position (using the Index of Relative Socio-
Economic Disadvantage22) from the NSWCR. Clinical
factors were patient comorbidity (using the Charlson
comorbidity index23 and diagnoses recorded in the
APDC in the month of diagnosis and the 5 years prior)
and extent of disease at diagnosis from the NSWCR.
Potential barriers to treatment were identified through
consultation with the Cancer Institute NSW’s Aboriginal
Advisory Group: attendance by a surgeon, medical oncol-
ogist or radiation oncologist (defined using MBS and
provider speciality codes; Table S1), minimum distance
required to travel to treatment, and possession of private
health insurance. Distance was measured from postcode of
residence to the nearest hospital with a relevant cancer-
specific multidisciplinary team (MDT) listed in CanRefer24
and active in 2012, and to the nearest radiotherapy facility
that was in operation at the time of diagnosis. Treatment
location for chemotherapy is harder to identify because of
the diverse mechanisms for chemotherapy delivery and
was not measured. Geodetic distance was calculated using
the geocode algorithm in SAS.25
Statistical analyses
Pearson Chi-squared tests with significance at α = 0.05
were used in unadjusted comparisons. Association
between treatment and Aboriginality was adjusted for
three risk adjustment sets using logistic regression
models for each cancer and treatment type. Adjustment
1 comprised age at diagnosis, sex, comorbidity and dis-
ease extent. Adjustment 2 additionally included remote-
ness and socioeconomic position. Adjustment 3
additionally included the potential treatment barriers.
Adjusted odds ratios (OR) are reported with 95% confi-
dence intervals (CI) and P-values. Statistical analyses
were performed using SAS version 9.4.
Results
There were 587 Aboriginal and 34 015 non-Aboriginal
people diagnosed with a first primary lung, breast or
bowel cancer included in the study (Fig. 1). The propor-
tions of colon, rectosigmoid and rectal cancers were simi-
lar for Aboriginal and non-Aboriginal people (P = 0.76,
not shown) so any differences in radiotherapy use due
to different treatment protocols for these cancers are not
expected. For each cancer type, Aboriginal people tended
to be diagnosed younger (P < 0.001), live more remotely
(P < 0.001) and have greater socioeconomic disadvantage
than non-Aboriginal people (P < 0.001; Table 1). At pre-
sentation, Aboriginal people had greater disease spread
for breast and bowel cancers (P = 0.05 and P = 0.003
respectively) and more comorbidities for lung cancer (P
= 0.003) compared with non-Aboriginal people.
The unadjusted results showed lower rates of lung sur-
gery (11.7% vs 15.9%, P = 0.09), and higher rates of breast
chemotherapy (59.2% vs 46.9%, P < 0.001), bowel radio-
therapy (20.5% vs 11.7%, P < 0.001) and bowel chemo-
therapy (50.0% vs 38.7%, P = 0.003) for Aboriginal people
compared with non-Aboriginal people (Table 3). Other
treatment modalities showed no significant differences.
Ideally a health system would provide similar treat-
ment to patients regardless of remoteness or wealth. This
was measured by adjusting for available patient and can-
cer characteristics that would clinically affect treatment
use: age, sex (except for breast cancer), comorbidity and
disease spread (Table 3, adjustment 1). Adjusted results
showed Aboriginal people received less surgery (OR
0.46, 95% CI 0.29–0.73, P < 0.001) or any treatment for
lung cancer (OR 0.64, 95% CI 0.47–0.88, P = 0.006)
than non-Aboriginal people. After further adjusting for
remoteness and socioeconomic disadvantage, the reduced
odds of receiving lung cancer surgery persisted (Table 3,
adjustment 2). For breast and bowel cancers, the signifi-
cantly higher chemotherapy rates for Aboriginal people
compared with non-Aboriginal people did not persist after
adjusting for age, disease extent, sex and comorbidity.
Radiotherapy use for bowel cancer tended to be higher
for Aboriginal people (OR 1.48, 95% CI 1.00–2.19,
P = 0.05; Table 3, adjustment 1).
Breast, lung, bowel cancers, 

















Figure 1 Study cohort.
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Table 1 Patient demographic and clinical characteristics by cancer diagnosis
Lung Breast Bowel
Aboriginal Non-Aboriginal Aboriginal Non-Aboriginal Aboriginal Non-Aboriginal
Number of people 230 8597 191 13 255 166 12 163
Age at diagnosis (years) P < 0.001 P < 0.001 P < 0.001
<60 78 (33.9%) 1492 (17.4%) 121 (63.4%) 6428 (48.5%) 71 (42.8%) 2870 (23.6%)
60–69 71 (30.9%) 2511 (29.2%) 47 (24.6%) 3531 (26.6%) 47 (28.3%) 3152 (25.9%)
70–79 63 (27.4%) 2622 (30.5%) 14 (7.3%) 1876 (14.2%) 37 (22.3%) 3379 (27.8%)
80+ 18 (7.8%) 1972 (22.9%) 9 (4.7%) 1420 (10.7%) 11 (6.6%) 2762 (22.7%)
Median (interquartile range) 66 (56–72) 71 (63–79) 54 (47–63) 60 (50–69) 62 (53–71) 70 (60–79)
Sex P = 0.38 P = 0.54
Male 128 (55.7%) 5034 (58.6%) 85 (51.2%) 6517 (53.6%)
Female 102 (44.3%) 3563 (41.4%) 191 (100%) 13 255 (100%) 81 (48.8%) 5646 (46.4%)
Remoteness of residence P < 0.001 P < 0.001 P < 0.001
Major cities 111 (48.3%) 6496 (75.6%) 100 (52.4%) 10 526 (79.4%) 89 (53.6%) 9152 (75.2%)
Inner regional 63 (27.4%) 1608 (18.7%) 47 (24.6%) 2168 (16.4%) 45 (27.1%) 2289 (18.8%)
Outer regional and remote 56 (24.3%) 493 (5.7%) 44 (23.0%) 561 (4.2%) 32 (19.3%) 722 (5.9%)
Area-based socioeconomic position P < 0.001 P < 0.001 P < 0.001
Least disadvantaged 6 (2.6%) 1120 (13%) 16 (8.4%) 3206 (24.2%) 5 (3.0%) 2179 (17.9%)
2nd quintile 20 (8.7%) 1355 (15.8%) 25 (13.1%) 2801 (21.1%) 21 (12.7%) 2287 (18.8%)
3rd quintile 28 (12.2%) 1618 (18.8%) 26 (13.6%) 2493 (18.8%) 33 (19.9%) 2318 (19.1%)
4th quintile 54 (23.5%) 1998 (23.2%) 52 (27.2%) 2481 (18.7%) 36 (21.7%) 2715 (22.3%)
Most disadvantaged 122 (53.0%) 2506 (29.1%) 72 (37.7%) 2274 (17.2%) 71 (42.8%) 2664 (21.9%)
Charlson comorbidity score P = 0.003 P = 0.28 P = 0.39
0 130 (56.5%) 5750 (66.9%) 171 (89.5%) 12 271 (92.6%) 129 (77.7%) 9904 (81.4%)
1 45 (19.6%) 1392 (16.2%) 9 (4.7%) 459 (3.5%) 15 (9.0%) 814 (6.7%)
2+ 55 (23.9%) 1455 (16.9%) 11 (5.8%) 525 (4.0%) 22 (13.3%) 1445 (11.9%)
Extent of disease at diagnosis P = 0.23 P = 0.05 P = 0.003
Localised 46 (20.0%) 1328 (15.4%) 80 (41.9%) 6555 (49.5%) 32 (19.3%) 3505 (28.8%)
Regional 51 (22.2%) 1852 (21.5%) 79 (41.4%) 5106 (38.5%) 90 (54.2%) 5209 (42.8%)
Distant 106 (46.1%) 4207 (48.9%) 23 (12.0%) 986 (7.4%) 38 (22.9%) 2535 (20.8%)
Unknown 27 (11.7%) 1210 (14.1%) 9 (4.7%) 608 (4.6%) 6 (3.6%) 914 (7.5%)









Number of people 230 8597 191 13 255 166 12 163
Visit to specialist
Oncologist† 144 (62.6%) 4754 (55.3%) 0.03 159 (83.2%) 10 777 (81.3%) 0.49 96 (57.8%) 5416 (44.5%) <0.001
Medical 107 (46.5%) 3747 (43.6%) 0.38 134 (70.2%) 8482 (64%) 0.08 89 (53.6%) 5121 (42.1%) 0.003
Radiation 95 (41.3%) 2941 (34.2%) 0.03 110 (57.6%) 8015 (60.5%) 0.42 28 (16.9%) 1407 (11.6%) 0.03
Surgeon 62 (27.0%) 2865 (33.3%) 0.04 156 (81.7%) 11 189 (84.4%) 0.30 126 (75.9%) 9649 (79.3%) 0.28
Minimum travel distance (km)
To surgery,
mean (SD)
104 (140) 31 (63) 73 (108) 20 (44) 85 (130) 31 (63)
To radiotherapy,
mean (SD)
99 (135) 29 (59) 88 (126) 24 (51) 81 (126) 30 (59)
Private health
insurance
21 (9.1%) 2513 (29.2%) <0.001 40 (20.9%) 7388 (55.7%) <0.001 37 (22.3%) 5427 (44.6%) <0.001
†Oncologist includes 14 people with oncologist visits that could not be classified as medical or radiation oncologists.
SD, standard deviation.
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Analysis of potential treatment barriers showed higher
rates of radiation oncologist visits among Aboriginal people
(41.3% vs 34.2%, P = 0.03; Table 2) diagnosed with lung
cancer, although radiotherapy use was similar (OR 1.20,
95% CI 0.93–1.57, unadjusted; Table 3). Aboriginal people
with lung cancer visited a surgeon less than non-Aboriginal
people (27.0% vs 33.3%, P = 0.04), consistent with less
surgery on an unadjusted basis (Table 3). There were no
Figure 2 Forest plots of multivariable adjusted odds ratios (OR) (with 95% confidence intervals) of receiving surgery, radiotherapy, chemotherapy or
any treatment for lung cancer. All variables are categorical except distance variables which shows odds change per 100 km.
Fitzadam et al.
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differences in the rates of seeing an oncologist or surgeon
between Aboriginal and non-Aboriginal women diagnosed
with breast cancer (Table 2). For bowel cancer, Aboriginal
people were more likely to have visited a medical or radia-
tion oncologist than non-Aboriginal people (P = 0.003 and
P = 0.03, respectively; Table 2), consistent with the higher
radiotherapy and chemotherapy rates in the unadjusted
results (Table 3). After adjusting for sex, age, disease extent
and comorbidities, a difference in oncologist visits was not
apparent for bowel cancer, although Aboriginal people
were less likely to attend a surgeon (OR 0.56, 95% CI
0.38–0.82, P = 0.003). For lung cancer, after these adjust-
ments surgeon visits remained lower (OR 0.59, 95% CI
0.43–0.81, P = 0.001) and radiation oncologist visits higher
for Aboriginal people (OR 1.33, 95% CI 1.01–1.76,
P = 0.04).
Figure 3 Forest plots of multivariable adjusted odds ratios (OR) (with 95% confidence intervals) of receiving surgery, radiotherapy, chemotherapy or
any treatment for breast cancer. All variables are categorical except distance variables which shows odds change per 100 km.
Cancer treatment for Aboriginal people
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For all three cancers, distance to nearest radiotherapy
centre or hospital with a specialist MDT was on average
around three times further for Aboriginal people compared
with non-Aboriginal people, and Aboriginal people had
significantly lower rates of private health insurance (P
< 0.0001).
Figure 4 Forest plots of multivariable adjusted odds ratios (OR) (with 95% confidence intervals) of receiving surgery, radiotherapy, chemotherapy or
any treatment for bowel cancer. All variables are categorical except distance variables which shows odds change per 100 km.
Fitzadam et al.
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The final model adjusted for distance to surgery, dis-
tance to radiotherapy, visit to a surgeon, medical oncolo-
gist or radiation oncologist and possession of private
health insurance, as well as sex, age, disease extent,
comorbidities, socioeconomic position and remoteness of
residence. Forest plots of the full model (adjustment 3;
Table 3) are shown in Figures 2 (lung), 3 (breast) and 4
(bowel). After this adjustment, odds of lung cancer sur-
gery were 0.75 for Aboriginal compared to non-Aborigi-
nal people, although the CI were wide (95% CI 0.04–
1.40, P = 0.37, adjustment 3; Table 3). Consultation with
oncologists or surgeon was strongly associated with
receiving treatment across all three cancers. In general,
distance to treatment was not a significant indicator of
receiving treatment when specialist visits were included
in the model. When specialist visits were removed from
the models, more distant travel to treatment significantly
reduced the odds of receiving lung surgery, lung radio-
therapy and breast radiotherapy.
Patients with private health cover had significantly
higher odds of receiving surgery, chemotherapy or any
treatment across all three cancer types (Figs 2–4).
Discussion
We found differences in lung cancer treatment between
Aboriginal and non-Aboriginal people in NSW. Despite
the relative youth of Aboriginal people diagnosed with
lung cancer, significantly fewer patients underwent sur-
gery compared with non-Aboriginal people. Thus treat-
ment differences found in earlier Australian studies
persist.11,13 In our study, after adjusting for sex, age, dis-
ease extent and comorbidities, we found Aboriginal peo-
ple with lung cancer were around 50% less likely to
have lung surgery compared with non-Aboriginal peo-
ple. Surgery is the recommended treatment for localised
non-small cell lung cancers, the tumour type that com-
prises the majority of lung cancer cases. Radiotherapy is
recommended for inoperable non-small cell lung cancers
or people unfit for surgery.26 However, radiotherapy use
was similar and overall treatment use across the three
modalities was 40% lower among Aboriginal people.
This is consistent with a case–control study in Queens-
land that identified lower odds of active treatment with
radiotherapy, chemotherapy or surgery among Aborigi-
nal people (46%, 72/158) compared with non-Aborigi-
nal people (72%, 109/152) after accounting for tumour
type, stage at diagnosis and comorbidities ascertained
from a medical record review.11
An important factor in receiving lung surgery was
consultation with a surgeon and Aboriginal people were
less likely to have a surgeon attendance. When surgeon
attendance was accounted for, distance to a hospital with
a lung MDT was not associated with receipt of surgery. A
NSW study reported that Aboriginal people with non-
metastatic non-small cell lung cancer who did not
receive surgery were more likely to be younger, from
major cities and without comorbidities.13 This highlights
the importance of referral pathways. Since 2015, the
Australian Optimal Care Pathway for lung cancer has
outlined the expected pathways of initial investigations,
referral, diagnosis and treatment for people presenting
with suspected lung cancer.27 Referral to a specialist who
is an MDT member is recommended for people with a
non-emergency presentation. To facilitate this referral,
localised optimal care pathways have been implemented
in areas in NSW using general practitioner decision aid
software that provide referral details for lung specialists
and for rapid access clinics.
One quarter of lung cancer diagnoses in NSW are via
an emergency hospital admission.28 Specialist consulta-
tions in an inpatient setting would not be captured in
our study. Emergency presentation has been linked to
lower use of potentially curative surgery.29 It is not
known if Aboriginal people are more likely to have an
emergency lung cancer diagnosis. People in the general
community delay seeking medical attention due to a per-
ceived lack of urgency about symptoms and stigma
around smoking.30 To help raise symptom awareness
and counteract fatalism a handbook on lung cancer for
Aboriginal and Torres Strait health workers has been
published.31 The handbook also provides information for
workers to support patients through treatment and reit-
erate their role in guiding other health professionals
about the cultural needs of Aboriginal people. Increasing
access to treatment, and importantly care that meets the
needs of Aboriginal people,32 is essential given that the
reported difference in lung cancer survival between
Aboriginal and non-Aboriginal people was mostly due to
lower rates of curative intent treatment.11
We found that treatment use in the NSW health sys-
tem was similar for Aboriginal and non-Aboriginal peo-
ple for breast and bowel cancers. There were no
differences found in treatment use for these cancers after
adjusting for sex, age, disease extent and comorbidities.
Our results provide evidence of progress in breast cancer
treatment for Aboriginal women in NSW, with an earlier
population-based study on women diagnosed 2001–
2007 finding more Aboriginal women did not receive
breast cancer surgery (15%, 43/288) compared with
non-Aboriginal women (11%, 3061/27 562) even after
adjustment for age, year of diagnosis, extent of disease,
comorbidity, rurality and socioeconomic position (OR
0.60, 95% CI 0.39–0.95, P = 0.03).8 We found similar
rates of breast-conserving surgery and mastectomy
among Aboriginal and non-Aboriginal women, as did
Cancer treatment for Aboriginal people
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studies in other Australian states33,34 although the previ-
ous NSW study reported higher mastectomy use among
Aboriginal women.8
There have been changes to breast cancer treatment
over recent decades with breast-conserving surgery with
adjuvant radiotherapy established as having equivalent
recurrence and survival outcomes to mastectomy for
early-stage breast cancer.35 Increased availability of radio-
therapy centres in regional NSW, with four centres open-
ing between 2007 and 2012 and a further two after our
study period, facilitates the uptake of breast-conserving
surgery and radiotherapy. Additionally, hypofractionated
radiotherapy regimens for early-stage breast cancer, which
reduce the standard course length from 5 to 3 weeks, have
become recommended treatment.36 Reduced travel time
and time away from home can make the choice of breast-
conserving surgery with radiotherapy compared to mas-
tectomy more acceptable.
For bowel cancer, our results strengthen findings from
an earlier population-based study in NSW that found
similar surgery rates between Aboriginal and non-
Aboriginal bowel cancer patients during 2001–2007.14
That study reported that adjuvant chemotherapy and
radiotherapy use for Aboriginal people, based on a medi-
cal record review of a sample of Aboriginal people diag-
nosed 2001–2010 (n = 145), was the same as that
reported in NSW population-based treatment pattern
surveys. Our study found no evidence of lower use of
chemotherapy and radiotherapy on a population basis.
The focus for breast and bowel cancers should be on
prevention, screening and earlier diagnosis for Aboriginal
people, who were diagnosed with more advanced disease
than their non-Aboriginal counterparts, similar to findings
from other studies.8,11,13,34 Participation by Aboriginal
people in the national bowel screening programme is esti-
mated to be half that of non-Aboriginal people (21% vs
43%).37 Participation by Aboriginal women in mammo-
graphic screening through BreastScreen NSW, although it
has increased, remains lower than non-Aboriginal women
(42% vs 53%).38 Screening programmes need to continue
to engage Aboriginal people in the planning and delivery
of services to improve participation.15
The primary strength of this study is its population basis
and the linked hospital, MBS and PBS data which pro-
vided comprehensive capture of outpatient radiotherapy
and chemotherapy treatments that may be poorly cap-
tured in studies relying on hospital record abstraction. Our
study also investigated potential barriers to treatment. Pri-
vate health insurance requires further exploration as
health insurance status may be functioning as a proxy for
health literacy or health-seeking behaviours which may
influence treatment choice. Our study used a robust
method of identifying Aboriginality.19 However, comparison
of our findings to earlier studies should be made with cau-
tion since apparent changes in outcomes for Aboriginal
people over time can be due to changes in people choos-
ing to self-identify as Aboriginal.39
The main limitation of our study is we could not mea-
sure if the treatment received was optimal guideline-
based therapy. We did not have qualitative factors such
as stigma, fatalism, individual choice and cultural safety
of care at hospitals that may act as barriers to treatment.
Another limitation is the study’s relatively old time
period due to unavoidable delays in linking the datasets.
We did not adjust for tumour histology or location,
which are known to affect receipt of lung resection,26
although there is no expectation these would vary by
Aboriginality and is unlikely to affect our findings.
Conclusion
We presented a comprehensive population-based study
of surgery, radiotherapy and chemotherapy treatments
for lung, breast and bowel cancers among Aboriginal
and non-Aboriginal people for the first time in NSW.
Our results provide evidence that overall treatment use
for breast and bowel cancer treatment for Aboriginal
people is equivalent to the rest of the community. How-
ever, Aboriginal people were 40% less likely than non-
Aboriginal people to have any treatment for lung cancer.
Underlying this, was fewer attendances with a surgeon
and lower use of surgery. There is a need to strengthen
referral pathways to lung cancer surgeons and specialist
MDT care for Aboriginal people.
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